TLDR
- Jaguar Health stock was down about 28% in Wednesday premarket trading to roughly $24.82 after soaring 1,190% Tuesday.
- Tuesday’s rally followed FDA fee waivers for Mytesi and Canalevia-CA1 and intense retail interest.
- Jaguar completed a 1-for-15 reverse stock split on Sept. 17, leaving roughly 520,000 common units outstanding.
- The fee waivers reduce regulatory costs but do not represent approval of a new drug.
- Jaguar is targeting a mid-2027 filing for crofelemer in pediatric microvillus inclusion disease, or MVID.
Jaguar Health (JAGX) stock reversed sharply Wednesday morning, falling about 28% in premarket trading to roughly $24.82. That followed an extraordinary 1,190% surge Tuesday, when the stock jumped from $2.67 to close at $34.46.
Earlier reports had JAGX rising another 11% premarket, but the move later reversed. The extreme volatility reflects the company’s very small post-split share count and a surge in retail trading interest.
Jaguar completed a 1-for-15 reverse stock split on Sept. 17 to support Nasdaq listing compliance. An SEC filing said the company had approximately 520,088 common units outstanding immediately after the split.
FDA Fee Waivers Sparked Tuesday’s Rally
The immediate company-specific catalyst came from the FDA. Jaguar said its Napo Pharmaceuticals business received a fiscal 2027 Prescription Drug User Fee Act waiver for Mytesi, while the FDA’s veterinary division separately waived fees for Canalevia-CA1.
Mytesi is already approved for noninfectious diarrhea in adults with HIV/AIDS receiving antiretroviral therapy. Canalevia-CA1 is conditionally approved for chemotherapy-induced diarrhea in dogs.
The waivers reduce fees associated with the two existing products. They should not be confused with new product approvals or clinical-trial results.
Both products are commercialized in the U.S. by Future Pak under a licensing arrangement. Jaguar continues to manufacture and supply them.
Rare-Disease Program Remains the Longer-Term Story
Jaguar is increasingly focused on crofelemer for rare gastrointestinal diseases. Its lead program targets MVID, a serious intestinal disorder that can leave children dependent on intravenous nutrition and fluids.
Jaguar says all randomized children in its MVID study are continuing into an extension phase. The company has also reported a reduction of up to 48% in intravenous support for one patient after extended crofelemer treatment.
Management is targeting a mid-2027 new drug application for MVID. The company is also pursuing a development and commercialization partner for the program.
The investor caveat is extreme volatility. JAGX remains a tiny biotechnology company with a history of reverse splits, losses and financing needs, while Tuesday’s rise was far larger than the economic value of the FDA fee waivers alone.
Wednesday’s sharp reversal reinforces that risk. Traders are now balancing the rare-disease opportunity against a very small float, dilution concerns and unusually speculative price action.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
